Volume 2 • Number 1
January 2003

MCT
Molecular Cancer Therapeutics

Articles

1–7	**Potential Involvement of the Cyclooxygenase-2 Pathway in the Regulation of Tumor-associated Angiogenesis and Growth in Pancreatic Cancer**	Jingsong Chu, Frank L. Lloyd, Ovidiu C. Trifan, Brian Knapp, and Maria Teresa Rizzo
9–17	**Negative Association of Melanoma Differentiation-associated Gene (*mda-7*) and Inducible Nitric Oxide Synthase (iNOS) in Human Melanoma: MDA-7 Regulates iNOS Expression in Melanoma Cells**	Suhendan Ekmekcioglu, Julie A. Ellerhorst, John B. Mumm, Mingzhong Zheng, Lyle Broemeling, Victor G. Prieto, Alexis L. Stewart, Abner M. Mhashilkar, Sunil Chada, and Elizabeth A. Grimm
19–28	**A Novel Form of the Plasminogen Activator Inhibitor Created by Cysteine Mutations Extends Its Half-Life: Relevance to Cancer and Angiogenesis**	Joanna Chorostowska-Wynimko, Rafal Swiercz, Ewa Skrzypczak-Jankun, Adam Wojtowicz, Steven H. Selman, and Jerzy Jankun
29–40	**Camptothecin Poly[*N*-(2-Hydroxypropyl) Methacrylamide] Copolymers in Antitopoisomerase-I Tumor Therapy: Intratumor Release and Antitumor Efficacy**	Moreno Zamai, Martin vandeVen, Mariella Farao, Enrico Gratton, Alberto Ghiglieri, Maria G. Castelli, Erminia Fontana, Roland d'Argy, Antonio Fiorino, Enrico Pesenti, Antonino Suarato, and Valeria R. Caiolfa
41–47	**Induction of DNA Damage Responses by Adozelesin Is S Phase-specific and Dependent on Active Replication Forks**	Jen-Sing Liu, Shu-Ru Kuo, Terry A. Beerman, and Thomas Melendy
49–58	**Clinically Potential Subclasses of Retinoid Synergists Revealed by Gene Expression Profiling**	Seiichi Ishida, Yukari Shigemoto-Mogami, Hiroyuki Kagechika, Koichi Shudo, Shogo Ozawa, Jun-ichi Sawada, Yasuo Ohno, and Kazuhide Inoue
59–64	**Effects of ER-37328 on Primary Tumor, Liver Metastasis, and Life Span in a Murine Colon 38 Orthotopic Transplantation Model**	Katsuji Nakamura, Tomoyoshi Taniguchi, Yasuhiro Funahashi, and Kentaro Yoshimatsu

cont'd

Articles (cont'd)

65–72	**Triptolide Inhibits the Growth and Metastasis of Solid Tumors**	Shanmin Yang, Jinguo Chen, Zhen Guo, Xue-Ming Xu, Luping Wang, Xu-Fang Pei, Jing Yang, Charles B. Underhill, and Lurong Zhang
73–81	**Flavopiridol-induced Apoptosis Is Mediated through Up-Regulation of E2F1 and Repression of Mcl-1**	Yihong Ma, W. Douglas Cress, and Eric B. Haura
83–93	**Protein Kinase C-dependent Activation of the Tumor Necrosis Factor Receptor-mediated Extrinsic Cell Death Pathway Underlies Enhanced Apoptosis in Human Myeloid Leukemia Cells Exposed to Bryostatin 1 and Flavopiridol**	Leanne Cartee, Sonia C. Maggio, Rebecca Smith, Heidi M. Sankala, Paul Dent, and Steven Grant
95–103	**Curcumin (Diferuloyl-Methane) Enhances Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis in LNCaP Prostate Cancer Cells**	Dorrah Deeb, Yong X. Xu, Hao Jiang, Xiaohua Gao, Nalini Janakiraman, Robert A. Chapman, and Subhash C. Gautam
105–112	**Reversal of Breast Cancer Resistance Protein-mediated Drug Resistance by Estrogen Antagonists and Agonists**	Yoshikazu Sugimoto, Satomi Tsukahara, Yasuo Imai, Yoshikazu Sugimoto, Kazumitsu Ueda, and Takashi Tsuruo
113–121	**Identification of the Polycomb Group Protein SU(Z)12 as a Potential Molecular Target for Human Cancer Therapy**	Antonis Kirmizis, Stephanie M. Bartley, and Peggy J. Farnham

i–iv *Instructions for Authors*

The Cover

PAI-1 reduces angiogenesis, but converts quickly into a latent form by retracting its reactive loop inside the molecule. Replacing chosen amino acids with novel cysteines creates -S-S- bridges (192–347, 197–355, 31–97, *red/green/yellow* structure) that extend half-life of the therapeutically desired active form from 2 up to over 700 h. For details, see Chorostowska-Wynimko *et al*. in this issue.